Asphyxia Associated Metabolite Biomarker Investigation (AAMBI)

Overview

Verification of biomarkers in a human population for their ability to diagnose the severity of neonatal asphyxia. These biomarkers linked to asphyxia have been identified in animal studies.

Full Title of Study: “Verification of Biomarkers to Examine Neonatal Asphyxia Induced Hypoxic-ischemic Encephalopathy. A Prospective Multicenter Observational Study for Development of a Diagnostic Test”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 27, 2017

Detailed Description

The aim of the study is to verify the application of combinations of several laboratory parameters in early postnatal blood samples, for identification of infants, who will suffer from early abnormal neonatal neurological outcome, in a population at risk. The population at risk is defined as term and late preterm (>36 weeks of gestation) human infants following perinatal hypoxia-ischemia with or without postnatal resuscitation.

Interventions

  • Other: blood sampling
    • small volume blood sampling, according to local laws, is not categorized as intervention (observational study)

Arms, Groups and Cohorts

  • Group 1
    • patients with hypoxic-ischemic encephalopathy (HIE) receiving hypothermia therapy
  • Group 2
    • patients with suspected HIE, non-confirmed
  • Group 3
    • healthy, retrospectively classified as such

Clinical Trial Outcome Measures

Primary Measures

  • abnormal short-term outcome (NE)
    • Time Frame: 14 days for clinical diagnosis
    • All patients are classified as abnormal short-term outcome (neonatal encephalopathy, NE) or normal short term outcome (no encephalopathy) by using clinical data, particularly Thompson score. For Group 1 and group 2 patients outcome classification will be additionally confirmed by using cranial ultrasound or MRI (including severe ischemia based on DWI or thalamic or cerebellar bleeding or arterial infarction or IVH>2° according to Papile, thalamic ischemia or severe cerebral edema) or seizure activity or burst suppression on aEEG or persistingly abnormal aEEG background pattern after complete rewarming. Bloodplasma samples will be analysed by a metabolomics approach using the p180-kit (Biocrates, Innsbruck, Austria). Metabolite concentrations or combinations thereof will be compared to the outcome described above in order to identify the most suitable metabolites to be used for early detection of NE in newborn infants.

Participating in This Clinical Trial

Inclusion Criteria

Group 1: inclusion criteria fulfilled for hypothermia treatment Group 2: Infants with suspected perinatal brain injury due to one of the followings

  • Perinatal hypoxia-ischemia (defined as a perinatal acidosis indicated by a pH≤7.10 or a base excess ≤-12mmol/l in umbilical cord blood or early postnatal blood collected at <90min of age (outborn patients) – 5min APGAR-score ≤ 5 – Need for resuscitation after birth for >1 min. after birth, positive pressure respiratory support with face mask or endotracheal tube, or cardiac compressions Group 3: UApH >7,25, and adaptation disorder of the newborn and need of postnatal clinical surveillance Exclusion Criteria:

gestational age < 36 weeks

  • age at time of screening >2,5h – congenital malformation – missing or invalid informed parental consent – unsuccessful resuscitation – infant considered not-viable – decision for palliative care only

Gender Eligibility: All

Minimum Age: 0 Hours

Maximum Age: 2 Hours

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Life Science Inkubator
  • Collaborator
    • Cukurova University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ron Meyer, Study Director, Life Science Inkubator Betriebs GmbH & Co. KG

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.